α-Glucosidase Inhibitors for Patients With Type 2 Diabetes
Response to Hanefeld et al.
- Floris A. van de Laar, MD and
- Peter L. Lucassen, MD, PHD
- Department of General Practice, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
- Address correspondence to Floris van de Laar, Radboud University Nijmegen Medical Centre, Department of General Practice, 229 HAG, P.O. Box 9101, 6500 HB Nijmegen, Netherlands. E-mail: f.vandelaar{at}hag.umcn.nl
Hanefeld et al. (1) assert that the conclusion (“no evidence for an effect on mortality or morbidity”) from our systematic review on the effects of α-glucosidase inhibitors for patients with type 2 diabetes was biased. Furthermore, they claim to have found evidence for such an effect based on their own meta-analysis. We disagree with both statements.
First, we would like to underline that the solid basis of our results is a systematic review and that meta-analyses were only applied when this was methodologically sound. The extensive search for all possible trials investigating α-glucosidase inhibitor monotherapy …
